Ticker: CTXR

Company: Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) What's happening inside the company - Citius is transitioning from development to commercial stage - FDA-approved LYMPHIR (denileukin diftitox) (approval Aug 8, 2024) and preparing a U.S. commercial launch targeted for Q4 2025. - The majority-o...